The Federal Trade Commission (FTC) recently appeared before the House subcommittee on Digital Commerce and Consumer Protection to request the power to impose meaningful civil penalties on companies that violate the nation’s data security and privacy protection laws. Currently, the FTC cannot impose fines on companies over privacy issues; however, if the public wants to see companies handle their sensitive information diligently, “the agency needs the ability to slap violators with fines and have more freedom to pass rules,” notes Law360. [Read more…]
The Federal Trade Commission (FTC) has made its first outright challenge towards so-called “no-authorized-generics” agreements between branded drug makers and generic drug companies. The agency initiated legal action against Endo Pharmaceuticals Inc. and other drugmakers for making anti-competitive payments through the mechanism of illegally withholding authorization for the production of generic versions of certain drugs. The FTC concludes these pharmaceutical companies violated antitrust laws by blocking lower-cost generic versions of branded drugs from consumers with pay-for-delay payments.